Drug Trial Radar · NCT03063762
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Last checked: Nov 19, 2026Latest source record: Feb 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Mar 20, 2017
Primary completion
Jun 14, 2021
Study completion Jun 14, 2021
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part.
Conditions
- Renal Cell Carcinoma
Interventions
AtezolizumabDrug
Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part. Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule
BevacizumabDrug
Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards. In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle.
RO6874281Drug
Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part. In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Arm A: It ends one week after the second administration of RO6874281 + atezolizumab Arm B: one week after the first administration of RO6874281 + atezolizumab + bevacizumab
- Maximum Tolerated Dose (MTD) of RO6874281Time frame: Arm A: It ends one week after the second administration of RO6874281 + atezolizumab Arm B: one week after the first administration of RO6874281 + atezolizumab + bevacizumab
- Recommended Dose of RO6874281Time frame: Arm A: It ends one week after the second administration of RO6874281 + atezolizumab Arm B: one week after the first administration of RO6874281 + atezolizumab + bevacizumab
- Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Screening until disease progression or study treatment discontinuation (assessed at every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to 24 months)
Locations
23 sites in 9 countries. Site status is shown where the registry gives one.
Yale Cancer Center; Medical Oncology
New Haven, Connecticut
Northwestern Center for Clinical Research; Cancer Center
Chicago, Illinois
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Herlev Hospital; Afdeling for Kræftbehandling
Herlev, Denmark
Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes
Lyon, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Universitätsklinikum Tübingen; Klinik für Urologie
Tübingen, Germany
Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTU
Würzburg, Germany
Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia
Modena, Emilia-Romagna, Italy
Fondazione IRCCS Policlinico San Matteo, Oncologia
Pavia, Lombardy, Italy
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital del Mar; Servicio de Oncologia
Barcelona, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain
Hospital Clínic i Provincial; Servicio de Oncología
Barcelona, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
Valencia, Spain
Clinica Universitaria de Navarra; Servicio de Oncologia
Pamplona, Navarre, Spain
Barts & London School of Med; Medical Oncology
London, United Kingdom
The Christie
Manchester, United Kingdom
Southampton General Hospital; Medical Oncology
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.